ArticleIndian journal of surgical oncology2025
AI Chatbots in Oncology: A Comparative Study of Sider Fusion AI and Perplexity AI for Gastric Cancer Patients.
Article in Indian journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GPU-Accelerated Artificial Intelligence Applications in Cancer Diagnosis, Imaging, and Treatment Planning.Asian Pacific journal of cancer prevention : APJCP · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The integration of AI chatbots in healthcare, particularly for young adults diagnosed with gastric cancer, offers a novel approach to enhancing patient support and information access. This evaluation examines the effectiveness of two AI chatbots, Sider Fusion AI Bot, and Perplexity AI, in improving patient outcomes, alleviating anxiety, and promoting informed decision-making. A comparative study design was employed, utilizing a structured rubric guided by experienced gastroenterologists to assess the performance of both chatbots. Evaluation criteria included competency, accuracy, relevance, informativeness, and support capabilities. The study focused on a case involving a 21-year-old male with advanced gastric adenocarcinoma. Both chatbots demonstrated high competency and relevance scores, achieving perfect scores of 5. However, they received low accuracy scores of 1, indicating a need for scrutiny in specific details. Sider Fusion AI Bot excelled in informativeness (score of 5) and support capabilities (rated "high"), while Perplexity AI scored 4 in informativeness and was rated "moderate" for support. Both systems provided essential recommendations for alleviating anxiety and emphasized informed decision-making, but Sider Fusion AI Bot offered a more comprehensive discharge plan. The study highlights the strengths and weaknesses of AI chatbots in oncology, emphasizing the importance of tailored communication styles to enhance patient engagement and outcomes. Sider Fusion AI Bot's superior capacity for detailed explanations and user engagement positions it as a potentially more valuable tool in clinical decision-making. Ongoing research is necessary to address limitations and optimize the integration of AI chatbots in healthcare settings, ensuring they effectively complement human interactions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.